From PharmaPhorum:
NICE has in first draft guidance rejected Bristol-Myers Squibb’s cancer immunotherapy, Opdivo (nivolumab), for use in advanced kidney cancer. NICE said it rejected Opdivo because it cost more than £60,000 per quality-adjusted life year gained in advanced renal cell carcinoma whose disease has progressed following previous treatment. This is above NICE’s normal £30,000 threshold and extra leeway given for drugs used at the end of life.
